Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects

Drugs in R and D

Volumn 10, Issue 4, 2010, Pages 225-242

  Nunes, Teresa ^a   Rocha, José F ^a   Vaz Da Silva, Manuel ^a   Igreja, Bruno ^a   Wright, Lyndon C ^a   Falcão, Amílcar ^b   Almeida, Luis ^c   Soares Da Silva, Patricio ^a,d  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b 4Health Ltd   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

^d University of Porto   (Portugal)

Author keywords

Antihypertensives; Dopamine beta hydroxylase inhibitors; Hypertension; therapeutic use; treatment

Indexed keywords

ACYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE; BIA 5453; BIA 5961; DRUG METABOLITE; ETAMICASTAT; N ACETYLTRANSFERASE 1; NORADRENALIN; PLACEBO; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOACCUMULATION; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; EAR INFECTION; ECG ABNORMALITY; FLATULENCE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LIMB PAIN; MACULOPAPULAR RASH; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NORADRENALIN URINE LEVEL; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; STEADY STATE; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION; URTICARIA; VOMITING;

EID: 79953219077     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11586310-000000000-00000     Document Type: Article

References (29)

1. Esler M, Kaye D. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol 2000;35(7 Suppl. 4): S1-7
2. Grassi G, Bolla G, Quarti-Trevano F, et al. Sympathetic activation in congestive heart failure: reproducibility of neuroadrenergic markers. Eur J Heart Fail 2008 Dec; 10(12):1186-91
3. Grassi G, Seravalle G, Quarti-Trevano F. The 'neuroadrenergic hypothesis' in hypertension: current evidence. Exp Physiol 2010 Dec. 11; 95(5):581-6
4. Lee CS, Tkacs NC. Current concepts of neurohormonal activation in heart failure: mediators and mechanisms. AACN Adv Crit Care 2008 Oct-Dec; 19(4):364-85
5. Mancia G, Grassi G, Giannattasio C, et al. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999;34(4 Pt 2):724-8 (Pubitemid 29501288)
6. Parmley WW. Neuroendocrine changes in heart failure and their clinical relevance. Clin Cardiol 1995;18(8):440-5
7. Pfeffer MA, Stevenson LW. Beta-adrenergic blockers and survival in heart failure. NEngl JMed 1996;334(21):1396-7 (Pubitemid 26152721)
8. Stanley WC, Li B, Bonhaus DW, et al. Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol 1997;121(8):1803-9 (Pubitemid 27343414)
9. Hegde SS, Friday KF. Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure. Curr Pharm des 1998;4(6):469-79 (Pubitemid 28536753)
10. Soares-da-Silva P. Evidence for a non-precursor dopamine pool in noradrenergic neurones of the dog mesenteric artery. Naunyn Schmiedebergs Arch Pharmacol 1986 Jul; 333(3):219-23 (Pubitemid 16076739)
11. Soares-da-Silva P. A comparison between the pattern of dopamine and noradrenaline release from sympathetic neurones of the dog mesenteric artery. Br J Pharmacol 1987 Jan; 90(1):91-8 (Pubitemid 17235598)
12. Gomes P, Soares-da-Silva P. Dopamine. In: Baden M, editor. Cardiovascular hormone systems: from molecular mechanisms to novel therapeutics. Weinheim: Wiley-VCH, 2008:251-93
13. Jose PA, Eisner GM, Felder RA. Role of dopamine receptors in the kidney in the regulation of blood pressure. Curr Opin Nephrol Hypertens 2002 Jan; 11(1):87-92 (Pubitemid 34053343)
14. Ishii Y, Fujii Y, Mimura C, et al. Pharmacological action of FD-008, a new dopamine beta-hydroxylase inhibitor: I, effects on blood pressure in rats and dogs. Arzneimittelforschung 1975;25:55-9
15. Kruse LI, Kaiser C, DeWolf Jr WE, et al. Multisubstrate inhibitors of dopamine beta-hydroxylase: 2, structureactivity relationships at the phenethylamine binding site. J Med Chem 1987;30:486-94 (Pubitemid 17033653)
16. Ohlstein EH, Kruse LI, Ezekiel M, et al. Cardiovascular effects of a new potent dopamine beta-hydroxylase inhibitor in spontaneously hypertensive rats. J Pharmacol Exp Ther 1987;241:554-9 (Pubitemid 17111562)
17. Beliaev A, Learmonth DA, Soares-da-Silva P. Synthesis and biological evaluation of novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopamine betahydroxylase. J Med Chem 2006;49(3):1191-7 (Pubitemid 43221665)
18. Kruse LI, Kaiser C, DeWolf Jr WE, et al. Substituted 1-benzylimidazole-2- thiols as potent and orally active inhibitors of dopamine beta-hydroxylase. J Med Chem 1986;29:887-9 (Pubitemid 16068793)
19. Igreja B, Wright L, Soares-Da-Silva P. Sustained antihypertensive effects of a selective peripheral dopamine-ß-hydroxylase inhibitor [abstract]. Hypertension 2007;50: e133
20. Beliaev A, Ferreira H, Learmonth DL, et al. Dopamine beta-monooxygenase: mechanism, substrates and inhibitors. Curr Enzyme Inh 2009;5:27-43
21. Nunes T, Rocha JF, Almeida L, et al. A rising single oral dose study to investigate the tolerability and pharmacokinetics of etamicastat, a new dopamine beta-hydroxylase inhibitor, in healthy male volunteers [abstract]. J Clin Pharmacol 2009;49:1094
22. Falcao A, Nunes T, Rocha JF, et al. Comparative bioavailability study of etamicastat (BIA 5-453) under fasted and fed conditions [abstract]. J Clin Pharmacol 2009;49:1095
23. Winter HR, Unadkat JD. Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos 2005;33:969-76 (Pubitemid 41002779)
24. *17 polymorphism in squamous cell cancer of head and neck. Carcinogenesis 2001 Sep; 22(9):1405-12 (Pubitemid 32898697)
25. Brocvielle H, Muret P, Goydadin AC, et al. N-acetyltransferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects. Skin Pharmacol Appl Skin Physiol 2003 Nov-Dec; 16(6):386-92 (Pubitemid 37256074)
26. Rychlik-Sych M, Skretkowicz J, Gawronska-Szklarz B, et al. Acetylation genotype and phenotype in patients with systemic lupus erythematosus. Pharmacol Rep 2006 Jan-Feb; 58(1):22-9
27. Deinum J, Steenbergen-Spanjers GC, Jansen M, et al. DBH gene variants that cause low plasma dopamine beta hydroxylase with or without a severe orthostatic syndrome [letter]. J Med Genet 2004 Apr; 41(4):e38
28. Walraven JM, Zang Y, Trent JO, et al. Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2. Curr Drug Metab 2008 Jul; 9(6):471-86 (Pubitemid 352025179)
29. Walraven JM, Trent JO, Hein DW. Structure-function analyses of single nucleotide polymorphisms in human N-acetyltransferase 1. Drug Metab Rev 2008;40(1):169-84 (Pubitemid 351220644)